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Abstract
Background:  Many randomized trials involve measuring a continuous outcome - such as pain,
body weight or blood pressure - at baseline and after treatment. In this paper, I compare four
possibilities for how such trials can be analyzed: post-treatment; change between baseline and post-
treatment; percentage change between baseline and post-treatment and analysis of covariance
(ANCOVA) with baseline score as a covariate. The statistical power of each method was
determined for a hypothetical randomized trial under a range of correlations between baseline and
post-treatment scores.
Results:  ANCOVA has the highest statistical power. Change from baseline has acceptable power
when correlation between baseline and post-treatment scores is high;when correlation is low,
analyzing only post-treatment scores has reasonable power. Percentage change from baseline has
the lowest statistical power and was highly sensitive to changes in variance. Theoretical
considerations suggest that percentage change from baseline will also fail to protect from bias in
the case of baseline imbalance and will lead to an excess of trials with non-normally distributed
outcome data.
Conclusions:  Percentage change from baseline should not be used in statistical analysis. Trialists
wishing to report this statistic should use another method, such as ANCOVA, and convert the
results to a percentage change by using mean baseline scores.
Background
Many randomized trials involve measuring a continuous
outcome at baseline and after treatment. Typical exam-
ples include trials of pravastatin for hypercholesterolem-
ia [1], exercise and diet for obesity in osteoarthritis
patients [2] and acupuncture for pain in athletes with
shoulder injuries [3]. In each trial, the outcome measure
used to determine the effectiveness of treatment - choles-
terol, body weight or shoulder pain - was measured both
before treatment had started and after it was complete.
In the case of a single post treatment outcome assess-
ment, there are four possibilities for how such data can
be entered into the statistical analysis of such trials. One
can use the baseline score solely to ensure baseline com-
parability and enter only the post-treatment score into
analysis (I will describe this method as "POST"). Alterna-
tively, one can analyze the change from baseline, either
by looking at absolute differences ("CHANGE") or a per-
centage change from baseline ("FRACTION"). The most
sophisticated method is to construct a regression model
which adjusts the post-treatment score by the baseline
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score ("ANCOVA"). Figure 1 describes each of these
methods in mathematical terms. Figure 2 gives examples
of the results of each method described in ordinary lan-
guage.
Some trials assess outcome several times after treat-
ment, a design known as "repeated measures." Each of
the four methods described above can be used to analyze
such trials by using a summary statistic such as a mean
or an "area-under-curve" [4]. There are several more
complex methods of analyzing such data including re-
peated measures analysis of variance and generalized
linear estimation [5]. These methods are of particular
value when the post-treatment scores have a predictable
course over time (e.g. quality of life in late stage cancer
patients) or when it is important to assess interactions
between treatment and time (e.g. long-term symptomat-
ic medication). This paper will concentrate on the sim-
pler case where time in not an important independent
variable.
The choice of which method to use can be determined by
analysis of the statistical properties of each. An impor-
tant criteria for a good statistical method is that it should
reduce the rate of false negatives (β ). The β  of a statistical
test is usually expressed in terms of statistical power (1-
β ). Power is normally fixed, typically at 0.8 or 0.9, and
the required amount of data (e.g. number of evaluable
patients) is calculated. A method that requires relatively
fewer data to provide a certain level of statistical power is
described as efficient.
The characteristics of the four methods - POST,
CHANGE, FRACTION and ANCOVA - have been studied
by statisticians for some time [6, 7, 8]. In this paper, I
aim to provide statistical data that can guide clinical re-
search yet is readily comprehensible by non-statisti-
cians. Accordingly, I will compare the methods using a
hypothetical trial and express results in terms of statisti-
cal power.
Methods
All calculations and simulations were conducted using
the statistical software Stata 6.0 (Stata Corp., College
Station, Texas). I created a hypothetical pain trial with
patients divided evenly between a treatment and a con-
trol group. The pain score for any individual patient was
sampled from a normal distribution. The mean score at
Figure 1
Mathematical description of the four methods
Figure 2
Examples of the results of a trial analyzed by each method in ordinary language terms
If b is the score at baseline, f is the score after treatment and g is treatment group: 
 
POST: Compare  f   by g 
FRACTION: Compare  100 x
b
b-f
 by g 
CHANGE: Compare b-f   by g 
ANCOVA: Calculate  f = constant + β 1 b + β 2 g and report β 2 
POST: Pain score was 10 points lower in the treatment group 
FRACTION: Pain fell by 40% in the treatment group but only 10% in controls 
CHANGE :Pain fell by 15 points more in the treatment group 
ANCOVA: After adjusting for baseline differences, pain fell by 15 points more in the 
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baseline was 50 mm on a visual analog scale of pain
(VAS); after treatment, mean pain was expected to be 50
mm in controls and 45 mm in treated patients. The
standard deviation of all scores was 10. The text of the
simulation is given in the appendix (appendix.doc).
I calculated the statistical power of the different methods
of analysis for this trial given a sample size of 100 pa-
tients. As power varies according to the correlation be-
tween baseline and follow-up scores, a range of different
possible correlations were used. The power for POST,
CHANGE and ANCOVA were calculated using the
"sampsi" function of Stata. This derives power analyti-
cally using formula developed by Frison and Pocock [6].
The power for FRACTION was calculated by the simula-
tion described above. The simulation was first validated
against Stata's results for POST and CHANGE at a corre-
lation of 0.5. It was then conducted using 1000 repeti-
tions calculating ttests for FRACTION at a range of
correlations between 0.2 and 0.8. The number of results
in which p was less than 5% was calculated.
Results and Discussion
The true positive rates of the four statistical methods giv-
en different correlations are given in table 1. These data
are equivalent to statistical power, or 1-β . As has been
previously reported [6], ANCOVA has the highest statis-
tical power. CHANGE has acceptable power when corre-
lation between baseline and post-treatment scores are
high;when correlations are low, POST has reasonable
power. FRACTION has poor statistical efficiency at all
correlations.
Moreover, the power of FRACTION is sensitive to chang-
es in the characteristics of the baseline distribution. If
the range of baseline values is large, the variance of
FRACTION increases disproportionately and power
falls. Simulations were repeated with the standard devi-
ations and difference between groups doubled. There
was no difference in the power of POST, CHANGE or
ANCOVA. The power of FRACTION fell dramatically: at
correlations of 0.2, 0.35, 0.5, 0.65 and 0.8 respectively,
power was 18%, 24%, 33%, 45% and 63%.
It is arguable that the method of simulation is biased
against FRACTION because the treatment effect is addi-
tive, that is, the simulation models an absolute 5 mm dif-
ference between groups. In theory, the difference
between FRACTION and CHANGE should decrease if
the treatment effect is proportional. The simulation was
therefore repeated with the treatment group experienc-
ing an average 10% decrease from baseline. Correlation
between baseline and follow-up scores was varied ran-
domly between 0.2 and 0.8. The p values from a ttest of
FRACTION and CHANGE were directly compared over
1000 simulations: p values were lower for CHANGE ap-
proximately 65% of the time.
Theoretical considerations suggestion two further disad-
vantages to FRACTION. First, because it incorporates
both baseline and post-treatment scores, it would appear
to control for any chance baseline imbalance between
groups. However, this is not the case because of regres-
sion to the mean: FRACTION will create a bias towards
the group with poorer baseline scores (the same is true
for CHANGE; POST causes bias in the opposite direc-
tion). Second, because it is calculated using a ratio, it
may cause outcome data to be non-normally distributed.
In a bivariate normal distribution (such as a baseline and
post-treatment score) any statistic using either variable
alone or combining both by addition or subtraction will
be normally distributed. There is no analytic reason why
a statistic created by multiplying or dividing one variable
by the other should necessarily have a normal distribu-
tion.
Conclusion
Reporting a percentage change from baseline gives the
results of a randomized trial in clinically relevant terms
immediately accessible to patients and clinicians alike.
This is presumably why researchers investigating issues
such as the effects of medication on hot flashes [9], or of
different chemotherapy regimes on quality of life [10],
report this statistic.
However, percentage change from baseline is statistical-
ly inefficient. Perhaps counterintuitively, it does not cor-
rect for imbalance between groups at baseline. It may
also create a non-normally distributed statistic from nor-
mally distributed data. Percentage change from baseline
should therefore not be used in statistical analysis. Trial-
ists wishing to report percentage change should first use
another method, preferably ANCOVA, to test signifi-
cance and calculate confidence intervals. They should
then convert results to percentage change by using mean
Table 1: Statistical power of each method of analysis
Correlation ρ  = 0.2 ρ  = 0.35 ρ  = 0.5 ρ  = 0.65 ρ  = 0.8
POST 70.5% 70.5% 70.5% 70.5% 70.5%
FRACTION 45.1% 56.4% 67.0% 82.7% 97.1%
CHANGE 50.7% 59.2% 70.5% 84.8% 97.7%
ANCOVA 72.3% 76.1% 82.3% 90.8% 98.6%BMC Medical Research Methodology (2001) 1:6 http://www.biomedcentral.com/1471-2288/1/6
baseline and post-treatment scores. For an example of
this approach, see Crouse et al. [11].
The findings presented here reconfirm previously re-
ported data suggesting that ANCOVA is the method of
choice for analyzing the results of trials with baseline and
post treatment measurement. In cases where ANCOVA
cannot be used, such as with small samples or where the
assumptions underlying ANCOVA modeling do not hold,
CHANGE or POST are acceptable alternatives, especially
baseline variables are comparable between groups (per-
haps ensured by stratification) and if correlation be-
tween baseline and post-treatment scores are either high
(for CHANGE) or low (for POST). The use of FRACTION
should be avoided.
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